Page 111 - Read Online

Page 248 Mohammadi et al. J Transl Genet Genom 2020;4:238-50 I https://doi.org/10.20517/jtgg.2020.29

understanding. Epilepsy Curr 2012;12:245-53.
2. Epilepsy. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy [Last accessed on 9 Jun 2020]
3. Fisher RS, van Emde BW, Warren B, Christian E, Pierre G, et al. Epileptic seizures and epilepsy: definitions proposed by the International
League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-2.
4. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med 2015;5:a022426.
5. Mormann F, Kreuz T, Andrzejak RG, David P, Lehnertz K, et al. Epileptic seizures are preceded by a decrease in synchronization.
Epilepsy Res 2003;53:173-85.
6. Moller RS, Hammer TB, Rubboli G, Lemke JR, Johannesen KM, et al. From next-generation sequencing to targeted treatment of non-
acquired epilepsies. Expert Rev Mol Diagn 2019;19:217-28.
7. Brunklaus A, Du J, Steckler F, Ghanty II, Johannesen KM, et al. Biological concepts in human sodium channel epilepsies and their
relevance in clinical practice. Epilepsia 2020;61:387-99.
8. Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, et al. Genetic and phenotypic heterogeneity suggest therapeutic
implications in SCN2A-related disorders. Brain 2017;140:1316-36.
9. Moller RS, Larsen LHG, Johannesen KM, Talvik I, Talvik T, et al. Gene panel testing in epileptic encephalopathies and familial
epilepsies. Mol Syndromol 2016;7:210-9.
10. Gardella E, Moller RS. Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia
2019;60:S77-85.
11. Kim JB. Channelopathies. Korean J Pediatr 2014;57:1-18.
12. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, et al. Ion channels in genetic epilepsy: from genes and mechanisms to disease-
targeted therapies. Pharmacol Rev 2018;70:142-73.
13. Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann
Neurol 2014;75:581-90.
14. Masnada S, Hedrich UBS, Gardella E, Schubert J, Kaiwar C, et al. Clinical spectrum and genotype-phenotype associations of KCNA2-
related encephalopathies. Brain 2017;140:2337-54.
15. Jiang X, Raju PK, D’Avanzo N, Lachance M, Pepin J, et al. Both gain-of-function and loss-of-function de novo CACNA1A mutations
cause severe developmental epileptic encephalopathies in the spectrum of Lennox-Gastaut syndrome. Epilepsia 2019;60:1881-94.
16. Strehlow V, Heyne HO, Vlaskamp DRW, Marwick FFM, Rudolf G, et al. GRIN2A-related disorders: genotype and functional
consequence predict phenotype. Brain 2019;142:80-92.
17. Shao LR, Habela CW, Stafstrom CE. Pediatric epilepsy mechanisms: expanding the paradigm of excitation/inhibition imbalance. Children
(Basel) 2019;6:23.
18. Marafiga JR, Pasquetti MV, Calcagnotto ME. GABAergic interneurons in epilepsy: more than a simple change in inhibition. Epilepsy
Behav 2020;106935.
19. Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 2013;26:440-9.
20. Wang J, Lin Z, Liu L, Xu HQ, Shi YW, et al. Epilepsy-associated genes. Seizure 2017;44:11-20.
21. Heyne HO, Singh T, Stamberger H, Jamra RA, Caglayan H, et al. De novo variants in neurodevelopmental disorders with epilepsy. Nat
Genet 2018;50:1048-53.
22. Maljevic S, Reid CA, Petrou S. Models for discovery of targeted therapy in genetic epileptic encephalopathies. J Neurochem
2017;143:30-48.
23. Reid CA, Berkovic SF, Petrou S. Mechanisms of human inherited epilepsies. Prog Neurobiol 2009;87:41-57.
24. Bando Y, Grimm C, Cornejo VH, Yuste R. Genetic voltage indicators. BMC Biol 2019;17:71.
25. Barker BS, Ottolini M, Wagnon JL, Hollander RM, Meisler MH, et al. The SCN8A encephalopathy mutation p.Ile1327Val displays
elevated sensitivity to the anticonvulsant phenytoin. Epilepsia 2016;57:1458-66.
26. Zeng SL, Sudlow LC, Berezin MY. Using Xenopus oocytes in neurological disease drug discovery. Expert Opinion on Drug Discovery
2020;15:39-52.
27. Quraishi IH, Stern S, Mangan KP, Zhang Y, Ali SR, et al. An epilepsy-associated KCNT1 mutation enhances excitability of human iPSC-
derived neurons by increasing slack KNa currents. J Neurosci 2019;39:7438-49.
28. Grabole N, Zhang JD, Aigner S, Ruderisch N, Costa V, et al. Genomic analysis of the molecular neuropathology of tuberous sclerosis
using a human stem cell model. Genome Med 2016;8:94.
29. Homan CC, Pederson S, To TH, Tan C, Piltz S, et al. PCDH19 regulation of neural progenitor cell differentiation suggests asynchrony of
neurogenesis as a mechanism contributing to PCDH19 girls clustering epilepsy. Neurobiol Dis 2018;116:106-19.
30. Higurashi N, Uchida T, Lossin C, Misumi Y, Okada Y, et al. A human dravet syndrome model from patient induced pluripotent stem cells.
Mol Brain 2013;6:19.
31. Liu Y, Lopez-Santiago LF, Yuan Y, Jones JM, Zhang H, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy
mechanism. Ann Neurol 2013;74:128-39.
32. Stanurova J, Neureiter A, Hiber M, Kessler HO, Stolp K, et al. Angelman syndrome-derived neurons display late onset of paternal
UBE3A silencing. Sci Rep 2016;6:30792.
33. Chamberlain SJ, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, et al. Induced pluripotent stem cell models of the genomic
imprinting disorders angelman and prader-willi syndromes. Proc Natl Acad Sci USA 2010;107:17668-73.
34. Bayat A, Hjalgrim H, Møller RS. The incidence of SCN1A-related dravet syndrome in denmark is 1:22,000: a population-based study
from 2004 to 2009. Epilepsia 2015;56:36-9.